Viral Conjunctivitis - Pipeline Review, H1 2018

  • ID: 4473109
  • Report
  • 34 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Adenovir Pharma AB
  • NanoViricides Inc
  • Panoptes Pharma GesmbH
  • Shire Plc
  • MORE
Viral Conjunctivitis - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Viral Conjunctivitis - Pipeline Review, H1 2018, provides an overview of the Viral Conjunctivitis (Ophthalmology) pipeline landscape.

Viral conjunctivitis, or pinkeye, is a common, self-limiting condition that is typically caused by adenovirus. Viral conjunctivitis is highly contagious, usually for 10-12 days from onset as long as the eyes are red. Symptoms include itchy eyes, tearing, redness, discharge and light sensitivity (with corneal involvement). Treatment includes lubricants, vasoconstrictors and antihistamines.

Report Highlights:

Pharmaceutical and Healthcare latest pipeline guide Viral Conjunctivitis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Viral Conjunctivitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Viral Conjunctivitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Viral Conjunctivitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 1 and 5 respectively.

Viral Conjunctivitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Viral Conjunctivitis (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Viral Conjunctivitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Viral Conjunctivitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Viral Conjunctivitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Viral Conjunctivitis (Ophthalmology)
Reasons to Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Viral Conjunctivitis (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Viral Conjunctivitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Adenovir Pharma AB
  • NanoViricides Inc
  • Panoptes Pharma GesmbH
  • Shire Plc
  • MORE
Introduction

Report Coverage

Viral Conjunctivitis - Overview

Viral Conjunctivitis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Viral Conjunctivitis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Viral Conjunctivitis - Companies Involved in Therapeutics Development

Adenovir Pharma AB

NanoViricides Inc

Panoptes Pharma GesmbH

Shire Plc

Viral Conjunctivitis - Drug Profiles

APD-209 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

APD-514 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EKCCide-I - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INV-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OKG-0301 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PP-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SHP-640 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Viral Conjunctivitis - Dormant Projects

Viral Conjunctivitis - Discontinued Products

Viral Conjunctivitis - Product Development Milestones

Featured News & Press Releases

Oct 11, 2012: Adenovir Pharma Announces Completion Of Phase I Study Of APD -209 To Treat Epidemic Keratoconjunctivitis

Aug 22, 2011: Researchers Discover New Drug To Treat Epidemic Keratoconjunctivitis

May 05, 2010: Foresight Biotherapeutics, Inc 's Drug FST-100 Reduces Infectious Adenoviral Titers And Improves Clinical Signs in Conjunctivitis Model

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Viral Conjunctivitis, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Viral Conjunctivitis - Pipeline by Adenovir Pharma AB, H1 2018

Viral Conjunctivitis - Pipeline by NanoViricides Inc, H1 2018

Viral Conjunctivitis - Pipeline by Panoptes Pharma GesmbH, H1 2018

Viral Conjunctivitis - Pipeline by Shire Plc, H1 2018

Viral Conjunctivitis - Dormant Projects, H1 2018

Viral Conjunctivitis - Discontinued Products, H1 2018

List of Figures:

Number of Products under Development for Viral Conjunctivitis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Adenovir Pharma AB
  • NanoViricides Inc
  • Panoptes Pharma GesmbH
  • Shire Plc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll